Firefly Neuroscience Inc (AIFF) - Business Payback Period
Firefly Neuroscience, Inc (AIFF) relies on a virtual EEG analysis infrastructure, which eliminates physical overhead and ensures stable data center operations. The company generates revenue by providing a cloud service for psychiatrists to digitally detect depression and Alzheimer's. This price chart confirms the asset's high market valuation of -1.80, driven by the brand's exceptional pricing power resulting from the integration of AI compliance into diagnostics.
Analytical breakdowns for Firefly Neuroscience, Inc
- stock price and consensus target price:
- market capitalization indicators:
- book capitalization data:
- company liabilities and liquidity data:
Aggregate Debt to Equity Firefly Neuroscience, Inc|AIFF - Long-Term Debt to Equity|Short-Term Debt to Equity Firefly Neuro|AIFF - Company Total Debt|Debts to Book Value Firefly Neuroscience, Inc.|AIFF - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Firefly Neuroscience|Immediate Liquidity Ratio fireflyneuro.com
- earnings and valuation multiples indicators:
AIFF - Net Profit|Expected Net Profit Firefly Neuroscience, Inc|AIFF - Price to Earnings Ratio|Forward P/E Multiple Firefly Neuroscience, Inc.|AIFF - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Firefly Neuroscience, Inc.|AIFF - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Firefly Neuroscience|AIFF - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months fireflyneuro.com|AIFF - Earnings growth in current year|Expected earnings per share growth for next year Firefly Neuroscience, Inc
- company sales and revenue statistics:
General company analysis:AIFF (fireflyneuro.com)
This indicator reflects the ratio between the market value of Firefly Neuroscience, Inc (AIFF) and its actual earnings, allowing for the determination of the asset's overvaluation relative to generated cash flows. By analyzing the company's average P/E, an investor assesses market expectations for the scaling of the BNA platform in clinics, where management's high competence in AI brain analytics may justify the current premium for future growth.
Competing companies
biogen.com - Market Cap to Net Income|P/E Multiple NBIX|Business Payback Period Regencell Bioscience Ltd|Price to Earnings Ratio Axsome Therapeutics Inc AXSM|Company Value to Net Income ACAD|Xenon Pharmaceuticals - P/E Multiple|Market Cap to Earnings vikingtherapeutics.com|SUPN: P/E Multiple|Market Cap to Net Income CPRX (Catalyst Pharma)|Price to Earnings Ratio Denali Therapeutics Inc|Price to Earnings Ratio HRMY|Price to Earnings Ratio BHVN (Biohaven Ltd.)|AMLX - Market Cap to Earnings|Trevi Therapeutics, Inc. - Price to Earnings Ratio|Company Value to Net Income PRAX|AVXL - Price to Earnings Ratio|CBLL (CeriBell EEG) - Price to Earnings Multiple|PRTA: P/E Multiple|Market Cap to Earnings Alector (ALEC)|Price to Earnings Ratio ANNX|P/E Multiple Omeros Corp.|Price to Earnings Ratio Neurogene Corp (NGNE)|ACIU (AC Immune Inc) - Company Value to Net Income|Price to Earnings Ratio Voyager Therapeutics VYGR|neumoratx.com (NMRA) - Market Cap to Earnings|SCLX - Price to Earnings Ratio|Business Payback Period Tevogen Bio Holdings Inc. TVGN|ACOG: P/E Multiple|Price to Earnings Ratio Cognition Therapeutics Inc.|IKT (Inhibikase Therapeutics) - P/E Multiple|cassavasciences.com (SAVA) - Business Payback Period|P/E Multiple ASRT|COYA - Market Cap to Earnings|Price to Earnings Ratio Vistagen VTGN|OVID: Price to Earnings Multiple|Acumen Pharmaceuticals - P/E Multiple|cervomed.com (CRVO) - Price to Earnings Ratio|ATHE: P/E Multiple|Market Cap to Earnings Clene (CLNN)|Price to Earnings Ratio PEPG|JUNS: Company Value to Net Income|P/E Multiple RLMD|Business Payback Period annovisbio.com|Price to Earnings Ratio Grace Therapeutics GRCE|KLTO: Price to Earnings Multiple|NeuroSense Therapeutics, Ltd. - P/E Multiple|Reviva Pharmaceuticals, Inc. (RVPH) - Price to Earnings Ratio|MTVA: P/E Multiple|neuraxis.com (NRXS) - P/E Multiple|HSDT (Helius Medical Technologies, Inc.) - P/E Multiple|Passage Bio Corp (PASG) - Business Payback Period|P/E Multiple NEUP|NERV: Market Cap to Net Income|P/E Multiple ATHA (Athira Pharma, Inc.)|ADXN (addextherapeutics.com) - Market Cap to Net Income|ALZN - Price to Earnings Ratio|CYCN (Cyclerion Therapeutics) - Price to Earnings Multiple|PTIX: P/E Multiple|Market Cap to Earnings Pasithea Therapeutics Corp. (KTTA)|Price to Earnings Ratio CRGT|P/E Multiple avenuetx.com|Price to Earnings Ratio BrainStorm Cell Therapeutics (BCLI)|CARA (Cara Therapeutics Inc.) - Company Value to Net Income|Price to Earnings Ratio Chromocell Therapeutics Corporation CHRO|Eliem Therapeutics, Inc. (ELYM) - Market Cap to Earnings|Intra-Cellular - P/E Multiple|Market Cap to Net Income LBPH|MRNS: P/E Multiple|NKGN - Business Payback Period|Price to Earnings Ratio NeuroBo|SAGE: Company Value to Net Income|P/E Multiple SNPX|TRVN - Market Cap to Earnings|P/E Multiple VIGL (Vigil Neuroscience, Inc.)|WENA (anewmeds.com) - Market Cap to Net Income|CERE - Price to Earnings Ratio
